Jiuyou Capital
VC Fund
Jiuyou Capital is a VC fund focused on Biotechnology and Medical. Jiuyou Capital has strong background resources in the fields of private equity investment institutions, public funds, wealth companies, banks, trusts, investment banks and brokerages. Relying on the shared economy model of “Internet + Social + Finance”, Jiuyou Capital is committed to building a more optimized and efficient investment industryecosystem, and thus becomes China's most influential financial resource integration and service platform.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Jiuyou Capital invests in
Stages Jiuyou Capital invests in
Countries Jiuyou Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $14M–$43M
- Series B
- $2.8M–$41M
- Series C
- $2.8M–$142M
Investment Focus
Industry
- Biotechnology 8 (50%)
- Medical 4 (25%)
- Health Care 4 (25%)
- Pharmaceutical 4 (25%)
- Biopharma 2 (13%)
Stage
- Series A 4 (25%)
- Series B 4 (25%)
- Series C 3 (19%)
- Angel 2 (13%)
- Funding Round 2 (13%)
Country
- China 11 (69%)
- Taiwan 1 (6%)
- United States 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sun Yi
Managing partner
|
Managing partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Jingxin Microelectronics
|
Jingxin Microelectronics is a developer of communication and information security chips including NRS1800, SDI3210, ESW5610, PRB0400 PCIe to SRIO and other chips and boards, enabling an efficient supply of high-speed data switching chips for the industry market. | $13.8M / Series B / May 20, 2024 | |
ReLive Biotechnologies LTD
|
ReLive is a biotechnology company that develops orthopedic sports medicine and plastic and reconstructive surgery projects based on regenerative medicine and cell therapy science. | $43M / Series A / Jan 16, 2023 | |
Maijing Gene
|
Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products. It is also committed to promoting the application of second-generation high-throughput sequencing technology in the field of precision medicine.Maijing Gene was established in 2015 and is based in Guangzhou,China. | Series C / Dec 29, 2022 | |
Jisi Yingda
|
Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development. | Series B / Nov 15, 2021 | |
OakMega
|
OakMega is a provider of cross-platform CRM solutions on messaging apps for marketing experts. Driven by honest values, and win-win mentality in their culture, OakMega is out to connect brands and people with human touch. | Series A / May 10, 2021 | |
Sinovent
|
Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation. Sinovent is centered around global standard excellence through its advanced biotechnology platform, decades of management experience, as well as financial support. Sinovent uniquely combines its expertise in science, management and finance, to develop and promoteadvanced treatment methods to solve worldwide healthcare problems. Currently, the company has 12 products in development, primarily in oncology, auto-immune diseases, and infectious diseases. | Dec 31, 2020 | |
Zenshine Pharma
|
Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on the development of small molecule drugs for cancer, viral infections, and autoimmune diseases. | $15M / Series A / Dec 01, 2020 | |
|
Sinovent
|
Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation. Sinovent is centered around global standard excellence through its advanced biotechnology platform, decades of management experience, as well as financial support. Sinovent uniquely combines its expertise in science, management and finance, to develop and promoteadvanced treatment methods to solve worldwide healthcare problems. Currently, the company has 12 products in development, primarily in oncology, auto-immune diseases, and infectious diseases. | $144.7M / Series C / Aug 25, 2020 | |
SmartNuclide
|
SmartNuclide is a biopharmaceutical company that develops biological drug products. | $2.8M / Series B / Apr 23, 2020 | |
Linpowave
|
Linpowave specializes in the research and development of millimeter-wave radar detection systems. | $7.1M / Nov 27, 2019 | |
| See all 16 investments → | |||
Co-Investors
Indaco Capital
2 deals together
Oceanpine Capital
2 deals together
ZJU Joint Innovation Investment
2 deals together
ABC International
1 deal together
Aurora Private Equity
1 deal together
Baidu Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Jiuyou Capital invest in?
Jiuyou Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Jiuyou Capital's check size?
Jiuyou Capital typically joins rounds of $14M–$43M at Series A, $2.8M–$41M at Series B and $2.8M–$142M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Jiuyou Capital participates in.
How do I contact Jiuyou Capital?
Public channels for Jiuyou Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Jiuyou Capital?
The team at Jiuyou Capital includes Sun Yi (Managing partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
